Clinical and regulatory intelligence for GRIN-related Neurodevelopmental Disorder with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Relevant assets

Phase →

Relevant companies

GRIN Therapeutics, Inc. →

Recent signals(1)

ClinicalJune 26, 2026

Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated

The Phase 3 trial for radiprodil in GRIN-NDD has commenced, focusing on efficacy and safety in two cohorts.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Neurology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.